Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published April 7, 2022 | Published
Journal Article Open

Validation of Candidate Sleep Disorder Risk Genes Using Zebrafish

Abstract

Sleep disorders and chronic sleep disturbances are common and are associated with cardio-metabolic diseases and neuropsychiatric disorders. Several genetic pathways and neuronal mechanisms that regulate sleep have been described in animal models, but the genes underlying human sleep variation and sleep disorders are largely unknown. Identifying these genes is essential in order to develop effective therapies for sleep disorders and their associated comorbidities. To address this unmet health problem, genome-wide association studies (GWAS) have identified numerous genetic variants associated with human sleep traits and sleep disorders. However, in most cases, it is unclear which gene is responsible for a sleep phenotype that is associated with a genetic variant. As a result, it is necessary to experimentally validate candidate genes identified by GWAS using an animal model. Rodents are ill-suited for this endeavor due to their poor amenability to high-throughput sleep assays and the high costs associated with generating, maintaining, and testing large numbers of mutant lines. Zebrafish (Danio rerio), an alternative vertebrate model for studying sleep, allows for the rapid and cost-effective generation of mutant lines using the CRISPR/Cas9 system. Numerous zebrafish mutant lines can then be tested in parallel using high-throughput behavioral assays to identify genes whose loss affects sleep. This process identifies a gene associated with each GWAS hit that is likely responsible for the human sleep phenotype. This strategy is a powerful complement to GWAS approaches and holds great promise to identify the genetic basis for common human sleep disorders.

Additional Information

© 2022 Tran and Prober. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Received: 10 February 2022; Accepted: 14 March 2022; Published: 07 April 2022. This work was funded by NIH grants R35NS122172 and R01MH121601 to DAP and a SRSF Career Development Award, Banting Postdoctoral Fellowship, and NSERC Postdoctoral Fellowship awarded to ST. Author Contributions. ST and DAP both contributed to the writing of this manuscript. All authors contributed to the article and approved the submitted version. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Edited by: Robert Gerlai, University of Toronto, Canada Reviewed by: Subhabrata Sanyal, California Life Company (Calico), United States Li-En Jao, University of California, Davis, United States

Attached Files

Published - fnmol-15-873520.pdf

Files

fnmol-15-873520.pdf
Files (3.8 MB)
Name Size Download all
md5:17922f749d45fcd4ccfb8c4aa3d1a43e
3.8 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
December 22, 2023